

A short update – Successful meetings for Emotra in Oviedo

During the past few days, on September 8–11, Emotra participated in the 16th European Symposium on Suicide and Suicidal Behaviour, ESSSB, in Oviedo, Spain. New, exciting studies on EDOR® were presented by research groups from Oviedo and Novara. In a study of 160 patients, the Oviedo group was able to rationally demonstrate that hyporeactivity is a strong biomarker for suicide, which is promising for the continued follow-up of our clinical multi-centre study, EUDOR-A. Professor Marco Sarchiapone was one of the keynote speakers at this conference and in his speech he presented EDOR® and EUDOR-A. He explained the conclusions from the baseline material and stated that the prospects of successful study results were good.

In his main speech, Marco Sarchiapone presented Emotra's method, EDOR®, in depth, and in a dedicated symposium on EDOR®, both Marco Sarchiapone and Emotra's head of research, Lars-Håkan Thorell, presented facts about the method and the ongoing EUDOR-A study, as well as the key conclusions from our baseline material analysis. A presentation that garnered a lot of attention was held by Patricia Burón, one of the researchers on the Oviedo team. She demonstrated an alternative approach in which hyporeactivity was compared with other known biomarkers for suicide. The group was able to convincingly show, with a 5.15 Odds Ratio, that hyporeactivity is a stronger marker of suicide risk than other indicators.

Naturally, we still have to confirm these new observations in our follow-up of EUDOR-A, but everyone agreed that the results were very promising.

A research team from Novara, Italy, presented a poster for a study conducted at the university on 177 patients using EDOR®. They concluded that hyporeactive people, compared to normally reactive ones, generally demonstrate a higher complexity of psychiatric diagnoses, somewhat abnormal personality traits, and in many cases lower self-esteem.

Both the Oviedo group's and the Novara team's studies showed that hyporeactivity is independent of socio-economic factors such as age, gender, etc.

On September 9 we held a meeting about our planned study, EUDOR-Y. The purpose of this study is to document testing with EDOR® on young people aged 12–20, with the goal of reducing the number of suicides among young people who suffer from depression. Our plan is for Emotra and the European Psychiatric Association's Suicide Section, EPASS, to conduct this study in collaboration. Suicide among young people is an enormous problem in the EU, and the trend is pointing steadily upward. Luckily, the number of clinics who have registered an interest in participating in this study has also increased steadily. A total of 26 clinics participated in this planning meeting in Oviedo.

"The meeting was a huge success. We clarified for the participants that our plans are still preliminary and that we are seeking to finance the study with the help of the European Commission's (EC) Horizon 2020 program. However, despite the uncertainty about the

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.



conditions for carrying out this study and when it could start, everyone strongly agreed on how important it is to proceed with this task. All of the participating clinics confirmed that they wish to participate in this project when the time comes to get it up and running”, Emotra’s CEO Claes Holmberg comments. “Their positive attitude to contributing to the documentation of EDOR® testing among young people is encouraged by the strong support expressed by the clinics involved in our EUDOR-A adult study. Everyone agrees that the method is easy to use and that the test itself is quick to administer”, Holmberg continues.

If we are granted financial support, we could start this study as early as the spring of 2017. We have already planned a kick-off meeting in Rome on March 31 – April 1, 2017. We will be submitting our application in October 2016. If it is turned down, we plan on resubmitting an amended application to the EC at the end of January 2017.

On September 10, “World Suicide Prevention Day”, the clinics participating in our EUDOR-A study convened for a meeting. At this meeting we presented and discussed the baseline material from our study. The meeting was in complete agreement with the conclusions that were published in Emotra’s press release dated July 27, 2016, and which were further clarified in a memo dated August 4, 2016. The general view was that these results indicate our study set-up is correct and that we, through our follow-up of the tested patients, should be able to demonstrate the expected connection between hyporeactivity and suicide.

The meeting also agreed on the logical conclusion that the vast majority of patients with self-injury disorders belong to a different group than patients who try to take their own lives. Most acts of self-injury are driven by either anxiety or a desire to let their surroundings and health care providers know that the patient is not feeling well. This effectively conceals the connection between hyporeactivity and previous suicide attempts, which disproves any strong connection between hyporeactivity and self-injury disorders.

The meeting also discussed how the study will be wound up in March 2017. Professor Sarchiapone underscored how important it is that everyone continuously submits their follow-up reporting to Rome. The clinics will be meeting in Rome on March 29–30, 2017 for a consensus meeting, which means that the group will come to an agreement on which conclusions can be drawn from the study results. Our plan is to present these results in connection with the important EPA Psychiatry Congress 2017, being held on April 1–4, 2017, in Florence, Italy.

In addition to these two meetings, Emotra hosted a dinner for 60 people representing both our current EUDOR-A study clinics and our future EUDOR-Y study clinics.

Our Publication Committee, PC, met separately at the Oviedo conference. The PC discussed the publication of a scientific article about our baseline material, other future publications and the disclosure of our follow-up results. After the meeting, the PC informed the clinics about the policy decisions reached. Several clinics have expressed an interest in carrying out their own studies and publishing scientific articles based on these. However, all such activities require prior approval by the PC.

“The Oviedo conference was a huge success for Emotra and EDOR®. Our method received much more attention than it did at this past spring’s successful conference in Madrid, for example. Since we

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company’s method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient’s response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.



started informing people about our operations in 2013, we have seen how attention for and interest in our method has increased steadily”, says Lars-Håkan Thorell, the method’s inventor and Emotra’s head of research. “I dare claim that European suicide researchers are very confident in how we are managing this effort, not least since Marco Sarchiapone gave Emotra his support. Many are very pleased about Emotra’s openness and our ambition of conducting this study in collaboration with suicide researchers. The reports from our ongoing multi-centre study, EUDOR-A, have generated very high hopes that a solution for the problem of being able to identify those patients who are at risk of taking their own lives is close at hand. At the end of March, we will know if we have managed to live up to these researchers’ expectations”, Emotra’s head of research concludes.

Later this autumn, Lars-Håkan Thorell will be presenting his research results in Chicago as one of the invited keynote speakers at a large and important international conference on bipolar disorders.

Emotra’s CEO, Claes Holmberg, will be presenting Emotra at MTI in London, England on September 20–21. He will also be holding a presentation of the company at the Swedish Shareholders’ Association’s meeting in Falköping on October 17 and at Stora Aktiedagen on November 14 in Göteborg.

For further information, please contact: *Claes Holmberg, CEO. Telephone: +46 708 25 45 47, E-mail: claes@emotra.se*

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company’s method, EDOR[®], is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient’s response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se